openPR Logo
Press release

Helix Research Center and AHRO Sign an MOU to provide GCP Training in Africa &Europe

07-18-2011 08:48 AM CET | Health & Medicine

Press release from: Helix Research Center Ltd

Inspired by the increasing demand for Trained Professionals in the Africa region and other parts of the World and inorder to contribute their share for ensuring strict GCP Compliance during clinical trials, Helix Research Center (HRC) and Africa Health Research Organization (AHRO) have signed a strategic working relationship on clinical trials program. The AHRO is a not for profit institution with offices spread across West Africa and United Kingdom

HRC will provide faculty members for AHRO’s training programs in Africa, develop the pre-requisite training materials to be adopted by AHRO for its training and provide capacity building skills training for volunteers/staff of AHRO who will be under the AHRO Clinical Trials Program. The core activities of AHRO includes evidence-based research, clinical trials, publication, events and community based intervention such as vaccination, supply of drugs to needy communities and intervention during public health emergence. The Chairman of HRC Dr Venkateswar Rao G,stated:”we are honored to be associated with AHRO which under leadership of dynamic,dedicated Clinician,Clinical Researcher ;Dr Abubakar Yaro has been working hard to lessen the burden of Diseases and alleviate Human Suffering in Africa and World in general.

For his part, Dr. Yaro, the CEO of AHRO praised the HRC for joining hands with AHRO on such an important venture stating:” We are really delighted and hopeful of this partnership. We are going to work extremely hard to be in the forefront of global clinical research activities”.

Prospective Trainees,both life sciences freshers and working Professionals and Scientific/Therapeutic Clinical Research Sponsors may contact AHRO or HRC for further details.

Helix Research Center Ltd is a London,UK based MNC providing Clinical Research,Healthcare,Consulting,Training at Services Worldwide and Africa Health Research Organisation is a Ghana based NGO providing Clinical Research,Healthcare and Educational Services

Helix Research Center Ltd,
Office 4,
219 Kensington High street,
W8 6BD,London,UK
Dr Venkateswar Rao G

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Helix Research Center and AHRO Sign an MOU to provide GCP Training in Africa &Europe here

News-ID: 183772 • Views: 1186

More Releases from Helix Research Center Ltd

Clinical Research Practices Concept to Expedite Global Clinical Trials
Having analysed and understood the Non Clinical & Clinical Trial outsourcing trends in the Global Clinical Research arena and the challenges by being endured by the stakeholders of Research & Development Industry;Viz the Pharmaceutical,Medical Device,Biotechnology and Cosmetic Industry Worldwide , the issues such as Financial constraints,safety and well being of Trial subjects,Errors,Misconducts,negative talk about the Clinical Trial activity itself in one or the other media and the need for introducing
Harmonised GCP Training Courses Launched by Helix Research Center
Inspired by the initiative of Sponsors of ICH ( International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals of Human Use) Viz,European Agency for the Evaluation of Medicinal Products ( EMEA),Japanese Ministry of Health,Labour and Welfare (JMHLW) and the US Food and Drug Administration (USFDA) , the Co Sponsors;Viz ,the European Federation of Pharmaceutical Industries' Associations (EFPIA),the Japanese Pharmaceutical Manufacturers Association (JPMA),the Pharmaceutical Research and Manufacturers of
Clinical Research Certificate Programs With Internship In India
It is an established fact that Clinical Research Industry is considered multibillion dollar industry and there can be no 'Recession' for the rapidly increasing dreadful diseases that cause high mortality and morbidity in almost every region of the World,irrespective any global economic slowdown/recession. But the Global Biopharmaceutical ,Medical Device and Cosmetic Industry and other Sponsors of R&D ( Research and Development) have been enduring many constraints including severe financial
Consulting,SMO & Site Support Services for the Global Clinical Trials
In view of the absolute necessity to ensure ,Safety and well being of Clinical Trial Subjects ,strict adherence to Good Clinical Practices Guidelines and Regulations governing Biomedical Research by Doctors of various Therapeutic areas such as Cardiology,Neurology,Oncology,Endocrinology,Pulmonology,Psychiatry,Obstetrics & Gynecology,Gastroenterology,Opthalmology,ENT,Internal Medicine,General Surgery etc,the need to produce quality data for a given study,reduce Regulatory delays,prevent avoidable errors and misconducts during a Clinical Trial,reduce the avoidable overheads for the Clinical Trial Sponsors such

All 5 Releases


More Releases for AHRO

Aluminium Rolling Oil Market 2020 - Increasing Demand, Growth Analysis and Futur …
Global Aluminium Rolling Oil Market Research Report 2020-2026, this title divided by product type, applications, industry verticals, and research regions build an in-depth explanation of the perspectives, and comprehensive market statistics. The report presents a thorough analysis of the Aluminium Rolling Oil Market covering key trends, deployment models, challenges, market drivers, future roadmap, ecosystem player profiles, strategies, and value chain. Global Aluminum Rolling Oil Market was valued at USD 45,139.3 Thousand
International Conference on Drug Therapy in TB Infection
6-7 January 2012, Edinburgh Scotland; Presented by AHRO The Africa Health Research Organization presents the International Conference on Drug Therapy in TB Infection TB remains one of the most important public health issue worldwide. Globally it is estimated that 8.8m new cases occur annually of these, 3.9m are smear positive. Although there is an effective therapy through the DOT strategy and majority of the global population are BCG vaccinated, the public